Could a cancer drug slow down these brain tumors?
NCT ID NCT03561870
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 study tested the drug olaparib in 35 people with recurrent IDH-mutant high-grade gliomas, a type of brain tumor. The goal was to see if olaparib could stop the tumor from growing for at least 6 months. Participants took olaparib tablets twice daily until their disease worsened or side effects became too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (a PARP inhibitor drug taken as tablets)
- What this could lead to
- If successful, olaparib could offer a new treatment option for people with recurrent IDH-mutant high-grade gliomas, potentially slowing tumor growth.
- What could go wrong
- This is a small, early-phase trial with only 35 participants. It may not show enough benefit, and olaparib can cause side effects like fatigue, nausea, or low blood counts.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUTANT HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospices Civils de Lyon
Bron, France